These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 8884160)

  • 1. Neurotoxicity of carbapenem antibacterials.
    Norrby SR
    Drug Saf; 1996 Aug; 15(2):87-90. PubMed ID: 8884160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk of seizures among the carbapenems: a meta-analysis.
    Cannon JP; Lee TA; Clark NM; Setlak P; Grim SA
    J Antimicrob Chemother; 2014 Aug; 69(8):2043-55. PubMed ID: 24744302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbapenems in serious infections: a risk-benefit assessment.
    Norrby SR
    Drug Saf; 2000 Mar; 22(3):191-4. PubMed ID: 10738843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tolerance and safety of carbapenems: the use of meropenem].
    Lizasoaín M; Noriega AR
    Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():73-7. PubMed ID: 9410074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is it safe to use carbapenems in patients with a history of allergy to penicillin?
    Sodhi M; Axtell SS; Callahan J; Shekar R
    J Antimicrob Chemother; 2004 Dec; 54(6):1155-7. PubMed ID: 15486083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants.
    Hornik CP; Herring AH; Benjamin DK; Capparelli EV; Kearns GL; van den Anker J; Cohen-Wolkowiez M; Clark RH; Smith PB;
    Pediatr Infect Dis J; 2013 Jul; 32(7):748-53. PubMed ID: 23838776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem.
    Wu Y; Chen K; Shi Z; Wang Q
    Curr Pharm Biotechnol; 2014; 15(8):685-90. PubMed ID: 25051950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem.
    Day IP; Goudie J; Nishiki K; Williams PD
    Toxicol Lett; 1995 Apr; 76(3):239-43. PubMed ID: 7762010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
    Kuo BI; Fung CP; Liu CY
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of seizures in pediatric cancer patients treated with imipenem/cilastatin.
    Karadeniz C; Oğuz A; Canter B; Serdaroğlu A
    Pediatr Hematol Oncol; 2000; 17(7):585-90. PubMed ID: 11033734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empiric carbapenem monotherapy in pediatric bone marrow transplant recipients.
    Nelson WK; Rayback PA; Quinones R; Giller RH
    Ann Pharmacother; 2002 Sep; 36(9):1360-5. PubMed ID: 12196052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meropenem: evidence of lack of proconvulsive tendency in mice.
    Patel JB; Giles RE
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():307-9. PubMed ID: 2808213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.
    Nakane T; Tamura K; Hino M; Tamaki T; Yoshida I; Fukushima T; Tatsumi Y; Nakagawa Y; Hatanaka K; Takahashi T; Akiyama N; Tanimoto M; Ohyashiki K; Urabe A; Masaoka T; Kanamaru A;
    J Infect Chemother; 2015 Jan; 21(1):16-22. PubMed ID: 25239059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
    Fournier A; Eggimann P; Pagani JL; Revelly JP; Decosterd LA; Marchetti O; Pannatier A; Voirol P; Que YA
    Burns; 2015 Aug; 41(5):956-68. PubMed ID: 25678084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of imipenem/cilastatin in neurocritical care patients.
    Hoffman J; Trimble J; Brophy GM
    Neurocrit Care; 2009; 10(3):403-7. PubMed ID: 19116700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective surveillance of imipenem/cilastatin use and associated seizures using a hospital information system.
    Pestotnik SL; Classen DC; Evans RS; Stevens LE; Burke JP
    Ann Pharmacother; 1993 Apr; 27(4):497-501. PubMed ID: 8477128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations.
    Miller AD; Ball AM; Bookstaver PB; Dornblaser EK; Bennett CL
    Pharmacotherapy; 2011 Apr; 31(4):408-23. PubMed ID: 21449629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem.
    Norrby SR; Newell PA; Faulkner KL; Lesky W
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():207-23. PubMed ID: 8543496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imipenem-cilastatin sodium, a broad-spectrum carbapenem antibiotic combination.
    Pastel DA
    Clin Pharm; 1986 Sep; 5(9):719-36. PubMed ID: 3530614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of in vivo nephrotoxicity in the rabbit by a pyrrolidinyl-thio Carbapenem CW-270031.
    Kim JM; Ha JR; Oh SW; Kim HG; Lee JM; Kim BO; Lee DG; Lee SH; Kim JG
    J Microbiol Biotechnol; 2008 Nov; 18(11):1768-72. PubMed ID: 19047819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.